Literature DB >> 11027678

Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.

Y Kliger1, S A Gallo, S G Peisajovich, I Munoz-Barroso, S Avkin, R Blumenthal, Y Shai.   

Abstract

DP178, a synthetic peptide corresponding to a segment of the transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus, type 1 (HIV-1), is a potent inhibitor of viral infection and virus-mediated cell-cell fusion. Nevertheless, DP178 does not contain gp41 coiled-coil cavity binding residues postulated to be essential for inhibiting HIV-1 entry. We find that DP178 inhibits phospholipid redistribution mediated by the HIV-1 envelope glycoprotein at a concentration 8 times greater than that of solute redistribution (the IC(50) values are 43 and 335 nm, respectively). In contrast, C34, a synthetic peptide which overlaps with DP178 but contains the cavity binding residues, did not show this phenomenon (11 and 25 nm, respectively). The ability of DP178 to inhibit membrane fusion at a post-lipid mixing stage correlates with its ability to bind and oligomerize on the surface of membranes. Furthermore, our results are consistent with a model in which DP178 inhibits the formation of gp41 viral hairpin structure at low affinity, whereas C34 inhibits its formation at high affinity: the failure to form the viral hairpin prevents both lipid and solute from redistributing between cells. However, our data also suggest an additional membrane-bound inhibitory site for DP178 in the ectodomain of gp41 within a region immediately adjacent to the membrane-spanning domain. By binding to this higher affinity site, DP178 inhibits the recruitment of several gp41-membrane complexes, thus inhibiting fusion pore formation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11027678     DOI: 10.1074/jbc.M004113200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level.

Authors:  Salomé Veiga; Sónia Henriques; Nuno C Santos; Miguel Castanho
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

2.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

5.  Site-directed antibodies against the stem region reveal low pH-induced conformational changes of the Semliki Forest virus fusion protein.

Authors:  Maofu Liao; Margaret Kielian
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  A peptide pertaining to the loop segment of human immunodeficiency virus gp41 binds and interacts with model biomembranes: implications for the fusion mechanism.

Authors:  Roberto Pascual; Miguel R Moreno; José Villalaín
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.

Authors:  Michael B Zwick; Richard Jensen; Sarah Church; Meng Wang; Gabriela Stiegler; Renate Kunert; Hermann Katinger; Dennis R Burton
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 8.  Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme.

Authors:  Judith M White; Sue E Delos; Matthew Brecher; Kathryn Schornberg
Journal:  Crit Rev Biochem Mol Biol       Date:  2008 May-Jun       Impact factor: 8.250

9.  Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.

Authors:  Mireille Guyader; Etsuko Kiyokawa; Laurence Abrami; Priscilla Turelli; Didier Trono
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 10.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.